FI953497A - Spirocykloalkylsubstituerade azetidinoner, som är användbara såsom hypokolesterolemiska medel - Google Patents

Spirocykloalkylsubstituerade azetidinoner, som är användbara såsom hypokolesterolemiska medel Download PDF

Info

Publication number
FI953497A
FI953497A FI953497A FI953497A FI953497A FI 953497 A FI953497 A FI 953497A FI 953497 A FI953497 A FI 953497A FI 953497 A FI953497 A FI 953497A FI 953497 A FI953497 A FI 953497A
Authority
FI
Finland
Prior art keywords
optionally
alkenylene
sum
substituted
image
Prior art date
Application number
FI953497A
Other languages
English (en)
Finnish (fi)
Other versions
FI953497A0 (sv
Inventor
Sundeep Dugar
John W Clader
Duane A Burnett
Margaret E Browne
Harry R Davis
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of FI953497A0 publication Critical patent/FI953497A0/sv
Publication of FI953497A publication Critical patent/FI953497A/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/12—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
FI953497A 1993-01-21 1995-07-20 Spirocykloalkylsubstituerade azetidinoner, som är användbara såsom hypokolesterolemiska medel FI953497A (sv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US643993A 1993-01-21 1993-01-21
PCT/US1994/000421 WO1994017038A1 (en) 1993-01-21 1994-01-19 Spirocycloalkyl-substituted azetidinones useful as hypocholesterolemic agents

Publications (2)

Publication Number Publication Date
FI953497A0 FI953497A0 (sv) 1995-07-20
FI953497A true FI953497A (sv) 1995-07-20

Family

ID=21720894

Family Applications (1)

Application Number Title Priority Date Filing Date
FI953497A FI953497A (sv) 1993-01-21 1995-07-20 Spirocykloalkylsubstituerade azetidinoner, som är användbara såsom hypokolesterolemiska medel

Country Status (26)

Country Link
US (1) US5698548A (sv)
EP (1) EP0681569B1 (sv)
JP (1) JP2719445B2 (sv)
KR (1) KR960700227A (sv)
CN (1) CN1118163A (sv)
AT (1) ATE199899T1 (sv)
AU (1) AU683048B2 (sv)
CA (1) CA2154257C (sv)
CZ (1) CZ180195A3 (sv)
DE (1) DE69426924T2 (sv)
DK (1) DK0681569T3 (sv)
EE (1) EE9400394A (sv)
ES (1) ES2155849T3 (sv)
FI (1) FI953497A (sv)
GR (1) GR3035963T3 (sv)
HU (1) HUT72592A (sv)
IL (1) IL108368A0 (sv)
LT (1) LT3595B (sv)
NO (1) NO952884L (sv)
NZ (1) NZ261714A (sv)
PL (1) PL309978A1 (sv)
PT (1) PT681569E (sv)
SI (1) SI9400022A (sv)
SK (1) SK91195A3 (sv)
WO (1) WO1994017038A1 (sv)
ZA (1) ZA94386B (sv)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5629295A (en) * 1992-06-26 1997-05-13 Pfizer Inc. Steroidal glycosides for treating hypercholesterolemia
US5631365A (en) * 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US5656624A (en) * 1994-12-21 1997-08-12 Schering Corporation 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents
US5648484A (en) * 1995-03-07 1997-07-15 Schering Corporation Catalytic enantioselective synthesis of a spriofused azetidinone
PT877750E (pt) * 1995-10-31 2002-09-30 Schering Corp 2-azetidinonas substituidas por acucar uteis como agentes hipocolesterolemiantes
US5756470A (en) * 1996-10-29 1998-05-26 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
AU4343500A (en) 1999-04-16 2000-11-02 Schering Corporation Use of azetidinone compounds
US6297268B1 (en) 1999-11-30 2001-10-02 Schering Corporation Imidazoles as cholesterol lowering agents
CA2432798C (en) * 2000-12-20 2007-02-27 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
AU2005246926B2 (en) * 2001-01-26 2008-02-28 Merck Sharp & Dohme Corp. The use of substituted azetidinone compounds for the treatment of sitosterolemia
CZ305202B6 (cs) * 2001-01-26 2015-06-10 Merck Sharp & Dohme Corp. Farmaceutický prostředek
US7071181B2 (en) * 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
RU2314126C2 (ru) * 2001-01-26 2008-01-10 Шеринг Корпорейшн Комбинации ингибитора (ингибиторов) всасывания стерина с модификатором (модификаторами) крови, предназначенные для лечения патологических состояний сосудов
EP1911462A3 (en) 2001-01-26 2011-11-30 Schering Corporation Compositions comprising a sterol absorption inhibitor
CA2442219C (en) 2001-03-28 2007-09-11 Schering Corporation Enantioselective synthesis of azetidinone intermediate compounds
US7056906B2 (en) * 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
AU2002336609B2 (en) * 2001-09-21 2006-08-24 Merck Sharp & Dohme Corp. Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors
SI1429756T1 (sl) * 2001-09-21 2007-02-28 Schering Corp Zdravljenje ksantomov z azetidinonskimi derivati kot inhibitorji absorpcije sterola
US20030204096A1 (en) * 2002-03-25 2003-10-30 Schering Corporation Enantioselective synthesis of azetidinone intermediate compounds
GB0215579D0 (en) 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds
US20040132058A1 (en) 2002-07-19 2004-07-08 Schering Corporation NPC1L1 (NPC3) and methods of use thereof
US7135556B2 (en) * 2002-07-19 2006-11-14 Schering Corporation NPC1L1 (NPC3) and methods of use thereof
AR040588A1 (es) 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
ATE485818T1 (de) * 2002-07-30 2010-11-15 Karykion Inc Zusammensetzungen aus ezetimib und verfahren zur behandlung von mit cholesterin zusammenhängenden gutartigen und bösartigen tumoren
JP4589919B2 (ja) 2003-03-07 2010-12-01 シェーリング コーポレイション 高コレステロール血症の処置のための、置換アゼチジノン化合物、これらの処方物および使用
US7235543B2 (en) * 2003-03-07 2007-06-26 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
AU2004233863B2 (en) 2003-04-24 2010-06-17 Incyte Holdings Corporation Aza spiro alkane derivatives as inhibitors of metalloproteases
JP2005015434A (ja) * 2003-06-27 2005-01-20 Kotobuki Seiyaku Kk 血清コレステロール低下剤或はアテローム性硬化症の予防又は治療剤
US20050096307A1 (en) * 2003-11-05 2005-05-05 Schering Corporation Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
EP1918000A2 (en) 2003-11-05 2008-05-07 Schering Corporation Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
AU2004308332B2 (en) * 2003-12-23 2008-04-10 Merck Sharp & Dohme Corp. Anti-hypercholesterolemic compounds
AU2004303742B2 (en) 2003-12-23 2008-06-19 Astrazeneca Ab Diphenylazetidinone derivatives possessing cholesterol absorption inhibitory activity
EP1723414A4 (en) * 2004-01-16 2008-03-26 Merck & Co Inc NPC1L1 (NPC3) AND METHOD FOR IDENTIFYING ITS LIGANDS
EP1598336A1 (en) 2004-05-20 2005-11-23 Laboratorios Del Dr. Esteve, S.A. Regioselective hydroxylation, functionalisation and protection of spirolactams
EP1676836A1 (en) * 2004-12-30 2006-07-05 Laboratorios Del Dr. Esteve, S.A. Regioselective hydroxylation, functionalisation and protection of spirolactams II
US20080045726A1 (en) * 2004-05-10 2008-02-21 Laboratorios Del Dr. Esteve, S.A. Spirolactams and Their Synthesis
EP1747197A1 (en) * 2004-05-10 2007-01-31 Laboratorios Del Dr. Esteve, S.A. Regioselective functionalisation and protection of spirolactams
US7291728B2 (en) 2004-05-10 2007-11-06 Laboratories Del Dr. Esteve, S.A. Spirolactams and their synthesis
WO2006039334A1 (en) * 2004-09-29 2006-04-13 Schering Corporation Combinations of substituted azetidonones and cb1 antagonists
ES2435790T3 (es) 2004-12-03 2013-12-23 Intervet International B.V. Piperazinas sustituidas como antagonistas de CB1
WO2006107936A1 (en) * 2005-04-04 2006-10-12 Pontificia Universidad Catolica De Chile The use of ezetimibe in the prevention and treatment of cholesterol gallstones
CN101243072A (zh) * 2005-06-20 2008-08-13 先灵公司 用作组胺h3拮抗剂的哌啶衍生物
SA06270191B1 (ar) 2005-06-22 2010-03-29 استرازينيكا ايه بي مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
JP2009521452A (ja) * 2005-12-21 2009-06-04 シェーリング コーポレイション コレステロール降下剤およびｈ３受容体アンタゴニスト／逆アゴニストを使用する非アルコール性脂肪性肝疾患の処置
EP1973877A2 (en) 2006-01-18 2008-10-01 Schering Corporation Cannibinoid receptor modulators
WO2007100807A2 (en) 2006-02-24 2007-09-07 Schering Corporation Npc1l1 orthologues
AR060623A1 (es) 2006-04-27 2008-07-02 Astrazeneca Ab Compuestos derivados de 2-azetidinona y un metodo de preparacion
CA2661404A1 (en) * 2006-09-05 2008-03-13 Schering Corporation Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis
CA2663500A1 (en) 2006-09-15 2008-03-20 Schering Corporation Spiro-condensed azetidine derivatives useful in treating pain, diabetes and disorders of lipid metabolism
WO2008033431A1 (en) * 2006-09-15 2008-03-20 Schering Corporation Spirocyclic azetidinone derivatives for the treatment of disorders of lipid metabolism, pain, diabetes and other disorders
WO2008033447A1 (en) * 2006-09-15 2008-03-20 Schering Corporation Azetidine and azetidone derivatives useful in treating pain and disorders of lipid metabolism
MX2009002922A (es) * 2006-09-15 2009-04-01 Schering Corp Derivados de azetidina y azetidona utiles en el tratamiento del dolor y de trastornos del metabolismo lipidico.
JP2010503678A (ja) * 2006-09-15 2010-02-04 シェーリング コーポレイション アゼチジノン誘導体およびその使用方法
MX2009002920A (es) * 2006-09-15 2009-04-01 Schering Corp Tratamiento del dolor, diabetes y trastornos del metabolismo de los lipidos.
CN101583612A (zh) * 2006-09-15 2009-11-18 先灵公司 治疗脂质代谢障碍的氮杂环丁酮衍生物
WO2008130616A2 (en) * 2007-04-19 2008-10-30 Schering Corporation Diaryl morpholines as cb1 modulators
BRPI0814806A2 (pt) 2007-06-28 2015-02-03 Intervet Int Bv Pirazinas substituídas como antagonistas de cb1
CA2694264A1 (en) * 2007-06-28 2009-01-08 Intervet International B.V. Substituted piperazines as cb1 antagonists
WO2010100255A1 (en) 2009-03-06 2010-09-10 Lipideon Biotechnology Ag Pharmaceutical hypocholesterolemic compositions
CN101993403B (zh) 2009-08-11 2012-07-11 浙江海正药业股份有限公司 氮杂环丁酮类化合物及医药应用
MX2012010772A (es) 2010-03-19 2012-11-06 Pfizer Derivados de 2,3-dihidro-1h-inden-1-il-2,7-diazaspiro[3,5]nonano y su uso como antagonistas o agonistas inversos del receptor de grelina.
US9763885B2 (en) 2012-05-01 2017-09-19 Althera Laboratories Ltd. Oral tablet formulation consisting of fixed combination of rosuvastatin and ezetimibe for treatment of hyperlipidemia and cardiovascular diseases
CN104496839B (zh) * 2014-12-03 2016-04-20 广东东阳光药业有限公司 取代环丁烷类神经氨酸酶抑制剂及其使用方法和用途
CN104496838B (zh) * 2014-12-03 2016-04-20 广东东阳光药业有限公司 取代环丁烷类神经氨酸酶抑制剂及其使用方法和用途
WO2020104930A1 (en) 2018-11-20 2020-05-28 Piramal Enterprises Limited An improved asymmetric synthesis of azaspiro compounds
CN113727732B (zh) 2019-03-20 2023-08-08 雷杰纳荣制药公司 用固醇调节元件结合转录因子1(srebf1)抑制剂治疗脂质水平升高
CA3133002A1 (en) 2019-03-20 2020-09-24 Regeneron Pharmaceuticals, Inc. Treatment of increased lipid levels with sterol regulatory element binding protein cleavage-activating protein (scap) inhibitors
WO2023122662A1 (en) * 2021-12-22 2023-06-29 The Regents Of The University Of California Covalently binding inhibitors of g12s, g12d and/or g12e mutants of k-ras gtpase

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2048080C3 (de) * 1970-09-30 1979-11-29 Basf Ag, 6700 Ludwigshafen Verfahren zur Herstellung von N-substituierten 33-disubstituierten ß -Lactamen
US4692515A (en) * 1984-09-24 1987-09-08 Pennwalt Corporation Adamantane-spirolactams
NZ228600A (en) 1988-04-11 1992-02-25 Merck & Co Inc 1-(benzylaminocarbonyl)-4-phenoxy-azetidin-2-one derivatives
US4983597A (en) 1989-08-31 1991-01-08 Merck & Co., Inc. Beta-lactams as anticholesterolemic agents
US5130425A (en) * 1990-10-12 1992-07-14 American Home Products Corporation Spiro-lactams and analogs thereof useful as aldose reductase inhibitors
MY131273A (en) * 1991-07-23 2007-07-31 Schering Corp Substituted beta-lactam compounds useful as hypocholesterolemic agents and processes for the preparation thereof

Also Published As

Publication number Publication date
NO952884D0 (no) 1995-07-20
FI953497A0 (sv) 1995-07-20
HUT72592A (en) 1996-05-28
SI9400022A (en) 1995-02-28
JP2719445B2 (ja) 1998-02-25
SK91195A3 (en) 1995-12-06
ATE199899T1 (de) 2001-04-15
AU6087294A (en) 1994-08-15
KR960700227A (ko) 1996-01-19
HU9502194D0 (en) 1995-09-28
EE9400394A (et) 1996-06-17
CA2154257A1 (en) 1994-08-04
EP0681569B1 (en) 2001-03-21
PL309978A1 (en) 1995-11-13
DE69426924T2 (de) 2001-08-16
AU683048B2 (en) 1997-10-30
US5698548A (en) 1997-12-16
CA2154257C (en) 1999-05-25
JPH08501110A (ja) 1996-02-06
NO952884L (no) 1995-09-20
ES2155849T3 (es) 2001-06-01
WO1994017038A1 (en) 1994-08-04
DK0681569T3 (da) 2001-04-23
ZA94386B (en) 1994-07-19
IL108368A0 (en) 1994-04-12
EP0681569A1 (en) 1995-11-15
NZ261714A (en) 1997-02-24
CN1118163A (zh) 1996-03-06
CZ180195A3 (en) 1996-01-17
GR3035963T3 (en) 2001-08-31
DE69426924D1 (de) 2001-04-26
LT3595B (en) 1995-12-27
PT681569E (pt) 2001-06-29
LTIP1764A (en) 1995-02-27

Similar Documents

Publication Publication Date Title
FI953497A0 (sv) Spirocykloalkylsubstituerade azetidinoner, som är användbara såsom hypokolesterolemiska medel
NO944911L (no) Ikke-peptid-takykininreseptorantagonister
AU6703786A (en) New medical use of tetrahydrocarbazolones derivative
RU95102778A (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования потерь костной ткани и снижения уровня холестерина в сыворотке, фармацевтический препарат, содержащий 2-фенил-3-ароилбензотиофен
RU94044436A (ru) Способы подавления атрофии кожи и влагалища
RU94045846A (ru) Применение производных бензотиофена для ингибирования тромбина
RU2009102832A (ru) С-фенил-1-тилоглюцитолы
CA2219050A1 (en) Polyamine derivatives as radioprotective agents
RU94045280A (ru) Средство для ингибирования патологических состояний молочных желез
RU94045156A (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования преждевременного полового созревания
ATE173252T1 (de) Arylmorpholine, herstellung und verwendung
TW261605B (sv)
AU4944899A (en) New pharmaceutically active compounds
AU2003253558A1 (en) Naphthamide derivatives and their use
AU6902800A (en) Pyridomorphinans and use thereof
RU94044323A (ru) Средство ингибирования навязчиво-компульсивных состояний и расстройств потребления
MX9302986A (es) Medicamento que contiene metrifonato y procedimiento para su preparacion
EE03518B1 (et) Farmatseutiline kompositsioon ja selle kasutamine
AU2788995A (en) Fungicidal mixtures
DK549085A (da) 3-aminopropoxyphenylderivater, fremgangsmaade til fremstilling deraf og farmaceutiske praeparater, som indeholder disse derivater
MX9601852A (es) Formulaciones de estramustina con propiedades farmaceuticas mejoradas.
AU8946391A (en) Cyclopentane ether derivatives, methods for preparing them and their use in pharmaceuticals
ES2155895T3 (es) Uso de 2-fenil-3-aroilbenzotiofenos para la preparacion de un medicamento para inhibir la hiperplasia endometrial primaria.
HU9401458D0 (en) Leukotriene-b4 derivatives, process for preparing the same and medicaments
NO952308D0 (no) Anvendelse av ruluzoler som radiorestaurator

Legal Events

Date Code Title Description
FD Application lapsed